Showing posts with label Asthma Therapeutics Market. Show all posts
Showing posts with label Asthma Therapeutics Market. Show all posts

Wednesday 14 June 2017

Asthma Therapeutics Market Analysis, opportunities Trends And Industry Strategies 2017 - 2025 - Credence Research

The latest market report published by Credence Research, Inc. “Global Asthma Therapeutics Market– Growth, Future Prospects and Competitive Analysis, 2016 – 2024” the global asthma therapeutics market was valued at US$ 19.35Bn in terms of value in 2015, and is expected to reach US$ 23.4Bn by 2024, expanding at a CAGR of 2.1% from 2016 to 2024.
Market Insights
Asthma is a chronic respiratory disease that affects the airways of the lung. There is no cure for asthma but it can be controlled by using different asthma symptoms controlling medications. Factors such as rise in asthma prevalence, increased environmental pollution, promising late-stage pipeline molecules and expected use of personalized medicine would further influence the market growth during forecast period. The global asthma therapeutics market is segmented on the basis of drug class, product type, route of administration and various geographic region.
Browse the full report Global Asthma Therapeutic Market- Growth, Future Prospects and Competitive Analysis, 2016 – 2024 at http://www.credenceresearch.com/report/global-asthma-therapeutics-market
There are mainly three types of drugs classes are used to treat asthma, it includes bronchodilators, anti-inflammatories and combination therapy. Currently once daily dose of combination drug consisting of beta agonist and inhaled corticosteroids trend is observed in the market and it is anticipated to grow moderately during forecast period. Currently, only one biologic Xolair is approved in market, but due to more efficacy with less side effects biologics market will preferred choice to treat asthma in future. Global asthma therapeutics market is segmented by product type such as dry powder inhalers, metered dose inhalers (MDIs), mist inhaler and nebulizers. Currently MDIs are dominating the market as they deliver consistent dose of medication directly to the lungs, however in recent years consumption pattern is shifting towards use of dry powder inhalers as they deliver more accurate dose with ease of use.
On the basis of route of administration, asthma therapeutics market is segmented as oral, inhalational and parenteral medication. In base year 2015, inhalation drug is major revenue contributing segment, factors such as rapid onset of action, less systemic toxicity and higher concentration availability at the site action are driving the market growth of inhalation asthma medication. Advair, Spiriva and Symbicort are the major contributors in inhaled asthma drug market. However patent expiry of some blockbusters drugs such as Symbicort and Flovent leads to reduce the overall revenue in global inhalation drug market. Currently North America is major revenue generating segment in global asthma therapeutics and it will show significant growth during forecast period 2016-2024. Increase in prevalence, rising population, high cost of medication, increasing demand of asthma medication, promising pipeline molecule would further drive the market growth in North America.
Market Competition Assessment:
The asthma therapeutics market is observed as the most competitive and comprises of large number of players. However, currently market is dominated by few players such as Abbott Laboratories, AstraZeneca, Becton, Dickinson and Company, Boehringer Ingelheim GmbH, Chiesi Farmaceutici, F. Hoffmann-La Roche, GlaxoSmithKline Plc., Merck& Co., Inc., Pfizer, Philips Healthcare, Sanofi-Aventis SA, Sunovion Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd. and others.
Key Market Movements:
Increase in prevalence, rising environmental pollution, promising late stage pipeline molecules, introduction of new technologies and expected use of personalized medicine would drive the market growth during forecast period.
Funding by the government agencies and private organizations, increasing healthcare awareness and economic development in some countries are key market growth drivers for the asthma therapeutics market.
Factors such as patent expiry of blockbuster drugs and under diagnoses of disease negatively impacting the market growth of asthma therapeutics market.
About Us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Who we are
Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.
Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.
Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.
What we do
We serve customers at each level of their organization, in whatever limit we can be most helpful, whether as a trusted counsel to top management or as a hands-on mentor for forefront representatives. For each engagement, we collect a group with the most suitable experience and ability.
No matter the challenge, we concentrate on delivering functional and persevering results, and preparing our customers to develop and lead. We join forces with customers to place suggestions into practice. Our research specialist work straightforwardly with customers over long stretches to create workforce aptitudes, drive operational change, and apply new working strategies.
Contact:
Name: Chris Smith
Designation: Global Sales Manager
Ph: 1-800-361-8290

Saturday 27 June 2015

Global Asthma Therapeutics Market Report Analysis, Growth,& Outlook 2015 - 2020

Market Research Reports Search Engine (MRRSE) has announced that its repository now features a report titled “ Asthma Therapeutics Market to 2020 – Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations.” The report, by GBI Research, forecasts that the market for asthma therapeutics will demonstrate marginal CAGR of 2.4% between 2013 and 2020. The forecast, which pertains to the top eight developed nations, estimates that the market will expand from its 2013 value of US$18.4 billion to US$21.7 billion by the end of 2020.

Asthma Therapeutics Market to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations

Meager as the growth may look, it is important to note that the asthma therapeutics market is on the verge of witnessing widespread generic erosion. Patent expirations are expected to eat into the revenues of blockbuster drugs such as Advair (fluticasone propionate/salmeterol xinafoate), Xolair (omalizumab), and Symbicort (budesonide/formoterol fumarate). This sea change in the global asthma therapeutics market will be brought about by the entry of new players as well as the growing pervasiveness of asthma itself.

The report notes that there is unparalleled industry interest in monoclonal antibodies and biologics, with the former enjoying more attention within the indication. Clinical trials have shown encouraging results for new monoclonal antibodies; some of these include: Lebrikizumab, mepolizumab, dupilumab target Interleukins (IL), and reslizumab. These molecules are seen to be beneficial in inadequately controlled or severe eosinophilic asthma. These drugs, which will constitute a sizeable chunk of the personalized asthma therapeutics market, will target a small section of asthma patients, but will carry steep price tags and still drive market growth. This, market experts predict, will ostensibly offset the detrimental effects of generic erosion.

Healthcare systems worldwide are already heaving the burden of growing incidences of asthma, show figures from the World Health Organization. The disease—which affected an estimated 300 million people worldwide in 2007—is projected to spread to 400 million people by 2025. While the better part of asthma patients are able to bring their symptoms under control using products currently available on the market, there is still a considerable chunk of asthma victims that cannot do so. This unmet need in the global asthma therapeutics market has kindled the interest of pharmaceutical companies and other industry players.

This has proven highly beneficial to the current asthma pipeline, with several promising molecules reported to be on the anvil. A number of these molecules are in the later stages of development and are expected to hit the asthma therapeutics market as early as 2015-16.